Authors' reply
Dr Lamb adds important information on the good stability of a1-microglobulin in the urine. This is noteworthy and con£icting data that we had not been aware of when compiling our references. 1 From this data, we concur with Dr Lamb that the stability of cystatin C and a1-microglobulin in the urine appear highly comparable, with similarly simple measurement and thus clinical applicability. Furthermore, Dr Lamb raises the important issue regarding the diagnostic value of each of these parameters. In our further study, urine cystatin C demonstrated a better prognostic value than a1-microglobulin di¡erentiating patients requiring renal replacement therapy from those not requiring replacement therapy in acute tubular necrosis. 2 However, this should only be considered a ¢rst study and our results require con¢rmation in a study with a larger patient sample before the question may be answered whether urinary cystatin C or a1-microglobulin provides better prognostic information in acute tubular necrosis.
Dimercaptosuccinic acid loading test for assessing mercury burden in healthy individuals
Neither the size of the study (n ¼14) nor the results presented justify the conclusions drawn byArchbold et al. in their recent paper on the DMSA (Kelmer, 2,3dimercaptosuccinic acid) test and urine mercury. 1 Strictly speaking, the comparison for assessing the e⁄cacy of this test should be made between subjects with and without dental amalgam^not Letters an easy study to set up^so the criticism of Hibberd et al. 2 for not using a group of asymptomatic, healthy individuals as controls can also be levelled at the present study, in which 11 of the 14 subjects showed evidence of excess mercury sequestration in the tissues (an increment in mercury excretion of greater than 150% in response to DMSA). An ideal response would be no increment in urine mercury (or indeed, no urine mercury at all). This demonstrates the widespread nature of the problem, not the failure of the Kelmer test to detect it. As the authors state, DMSA is generally safe, even when administered I.V. and in much higher doses than 30 mg/kg (the relatively mild oral challenge used in the Kelmer test). Reactions, as described by the authors, are associated with hypersensitivity to mercury as it is mobilized from the tissues, rather than to DMSA itself.
We have carried out 3796 Kelmer challenge tests over the past 6 years and in our opinion this is a reasonable and practicable (although by no means perfect) method of assessing excess sequestered body mercury. The symptoms of a variety of chronic illnesses recede with mercury removal from the body and this can be followed with sequential Kelmer tests. In most cases the mercury derives from leaking dental amalgams (there is no expected simple correlation with the number or area of exposed ¢llings).
Confounding factors in the test include prior administration of chelating agents and raised initial urine mercury concentrations (which may reduce the incremental change in urine mercury with DMSA) and the fact that the release of DMSA-bound mercury can have a diuretic e¡ect (diluting the second urine sample).
Most of the criticisms of the Kelmer test derive from the unfortunate determination of some dentists (and laboratory scientists) to prove that there is no hazard associated with the use of mercury in the mouth, in spite of mounting clinical evidence to the contrary.
Nicholas J Miller, Mark A Howard
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Dimercaptosuccinic acid loading test for assessing mercury burden in healthy individuals
The source of the Hibberd et al. paper, 2 referred to by Archbold et al., 1 was The Bayswater Clinic, London, which provided the patients and carried out the clinical assessments. Biolab Medical Unit, London, the laboratory referred to, carried out biochemical and statistical analyses for the paper.
Whilst the Kelmer test [employing dimercaptosuccunic acid (DMSA)] for body mercury load, subsequently o¡ered by the laboratory, arose from suggestions of Hibberd et al., 2 that paper made no mention of a normal range for such a test. Such a range is not applicable because: (a) reduced excretion of mercury is a factor in development of toxicity in some cases; and (b) there is not a speci¢c 'no observed e¡ect level for mercury vapour', considered the most important form determining human exposure to amalgams. 2 Hence there is the danger of an erroneous assumption of no mercury toxicity whenever a result falls within such a range.
All patients carry some mercury, and those who have, or have had, amalgams carry a higher load. 2 My observations over 20 years indicate that over 95% of the UK population who have received dental treatment have, or have had, amalgams. Because constant mercury release from amalgams (particularly as vapour), leads to the very toxic mercuric ion which binds at multiple tissue sites throughout the body causing major enzyme and cellular dysfunction, one would be extremely hard pressed to ¢nd a truly asymptomatic healthy control group, as Archbold et al. 1 suggest.
Hibberd et al. 2 listed various mild side e¡ects, very likely due to mercury mobilization. The case of serious hypersensitivity reported by Archbold et al. 1 in the small group of 15 volunteers raises the question, should that subject have been accepted into the study? Their volunteers were classi¢ed asymptomatic and healthy on the basis of their own subjective assessments; no biochemical data or medical histories were obtained. Also, the assumption is made that DMSA caused the hypersensitivity. It may have arisen, after only 6 minutes, from a capsule shell constituent, there being little time for dissolution.
Archbold et al. 1 draws a comparison between no hypersensitivity being observed in the one dose study of Hibberd et al. 2 with various side e¡ects, including hypersensitivity, described in cases of prolonged DMSA treatment, which is misleading. DMSA has proved to be well tolerated with a wide therapeutic index. 2 The Kelmer test, employed with various other methods of assessment, has provided most useful
